Suppr超能文献

通过血清蛋白质组图谱诊断食管腺癌。

Diagnosis of esophageal adenocarcinoma by serum proteomic pattern.

作者信息

Hammoud Zane T, Dobrolecki Lacey, Kesler Kenneth A, Rahmani Emad, Rieger Karen, Malkas Linda H, Hickey Robert J

机构信息

Department of Surgery, Cardiothoracic Surgery Division, Indiana University School of Medicine, Indianapolis, Indiana 46202, USA.

出版信息

Ann Thorac Surg. 2007 Aug;84(2):384-92; discussion 392. doi: 10.1016/j.athoracsur.2007.03.088.

Abstract

BACKGROUND

Currently, endoscopic biopsy is the only method used to diagnose esophageal adenocarcinoma. Using surface-enhanced laser desorption/ionization (SELDI) ProteinChip technology, we sought to identify a potentially diagnostic serum protein pattern that can serve as a reliable blood test for the diagnosis of esophageal adenocarcinoma. In addition, we sought to identify potential biomarkers for esophageal adenocarcinoma.

METHODS

Whole serum was collected using standard techniques from subjects with a known diagnosis of esophageal adenocarcinoma as well as from subjects without any known esophageal disease. The samples were spotted onto a hydrophobic (H50) and immobilized metal affinity (IMAC30) chip surface and allowed to incubate. All samples were run in duplicate. After several washes, matrix was added and a mass range of 1500 to 30000 daltons was analyzed by SELDI-Time-of-Flight mass spectroscopy. Statistical analysis was performed using Biomarker Pattern Software (Bio-Rad Laboratories, Hercules, CA).

RESULTS

For the H50 analysis, 3 peaks were identified that correctly diagnosed 42 of 43 cancers and 10 of 11 normals. For the IMAC30, 4 peaks were identified that correctly diagnosed 50 of 50 cancers and 10 of 10 normals.

CONCLUSIONS

Serum proteomic pattern shows great promise in the diagnosis of esophageal adenocarcinoma. This technology may lead to the development of a noninvasive screening test as well as to the identification of potential novel biomarkers for esophageal adenocarcinoma.

摘要

背景

目前,内镜活检是诊断食管腺癌的唯一方法。我们利用表面增强激光解吸/电离(SELDI)蛋白质芯片技术,试图识别一种潜在的诊断性血清蛋白质模式,它可作为一种可靠的血液检测手段用于食管腺癌的诊断。此外,我们还试图识别食管腺癌的潜在生物标志物。

方法

采用标准技术从已知诊断为食管腺癌的受试者以及无任何已知食管疾病的受试者中采集全血血清。将样本点样到疏水(H50)和固定化金属亲和(IMAC30)芯片表面并进行孵育。所有样本均重复检测。经过多次洗涤后,加入基质,并通过SELDI飞行时间质谱分析1500至30000道尔顿的质量范围。使用生物标志物模式软件(Bio-Rad实验室,加利福尼亚州赫拉克勒斯)进行统计分析。

结果

对于H50分析,识别出3个峰,它们正确诊断了43例癌症中的42例以及11例正常样本中的10例。对于IMAC30,识别出4个峰,它们正确诊断了50例癌症中的50例以及10例正常样本中的10例。

结论

血清蛋白质组模式在食管腺癌的诊断中显示出巨大潜力。这项技术可能会促成一种非侵入性筛查检测方法的开发,以及食管腺癌潜在新生物标志物的识别。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验